Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: II. Double-blind, placebo-controlled EEG mapping and psychometric studies under hypoxia

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 18, Issue 1, 1996, Pages 67-81

  Saletu, Bernd ^a   Grünberger, Josef ^a   Anderer, Peter ^a   Linzmayer, Leopold ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

antiglutamate; brain protection; EEG mapping psychometry; hypoxia; hypoxic hypoxidosis; noopsyche; riluzole; thymopsyche; transient organic brain syndrome

Indexed keywords

PLACEBO; RILUZOLE;

ADULT; ARTICLE; BEHAVIOR; BLOOD GAS ANALYSIS; BRAIN FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; HYPOXIA; MALE; NEUROPROTECTION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PARESTHESIA; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADULT; AFFECT; ALTITUDE; ANALYSIS OF VARIANCE; ANOXIA; BLOOD GAS ANALYSIS; BRAIN; BRAIN MAPPING; DELTA RHYTHM; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEUROPROTECTIVE AGENTS; PSYCHOMETRICS; RILUZOLE; THETA RHYTHM; THIAZOLES;

EID: 0029876272     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Bensimon, G., Lacomblez, L., Meininger, V., ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl J Med 1994, 330: 585-91.
2. Malgouris, C., Bardot, F., Daniel, M. et al. Riluzole, a novel antiglutamate, prevents memory: loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci 1989, 9: 3720-7.
3. Pratt, J., Rataud, J., Bardot, F. et al. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischemia. Neurosci Leu 1992, 140 (2): 225-30.
4. Wahl, F., Doble, A., Allix, M., Plotkine, M., Boulu, R.G. Effect of riluzole on focal cerebral ischemia in rats. Eur J Pharmacol 1993, 230: 209-14.
5. Saletu, B., Grünberger, J. Cerebral hypoxic hypoxidosis: Neurophysiological, psychometric and pharmacotherapeutic aspects. In: Advances in Biological Psychiatry. Karger: Basel 1983, 146-64.
6. Saleiu, B., Grünberger, J. The hypoxia model in human psychopharmacology: Neurophysiological and psychometric studies with aniracetant i.v. Human Neurobiol 1984, 3: 171-81.
7. Saletu, B., Grünberger, J., Anderer, P. Proof of antihypoxidotic properties of tentlsetam in man by EEG and psychometric analyses under an experimental hypoxic hypoxidosis. Drug Dev Res 1987, 10: 135-55.
8. Saletu, B., Anderer, P., Grünberger, J. EEG brain mapping in gerontopsychopharmacology: On protective properties of pyritinol against hypoxic hypoxidosis. Psychiatry Res 1989, 29 (3): 387-90.
9. Saletu, B., Grünberger, J., Linzmayer, L., Anderer, P. Brain protection of nicergoline against hypoxia: EEG brain mapping and psychometry. J Neural Transm Park Dis Dement Sect 1990, 2: 305-25.
10. Saletu, B., Grünberger, J., Anderer, P. On brain protection of co-dergocrine mesylate (Hydergine ®) against hypoxic hypoxidosis of different severity: Double-blind placebo-controlled quantitative EEG and psychometric studies. Int J Clin Pharmacol Ther Toxicol 1990, 28: 510-24.
11. Saletu, B., Grünberger, J., Linzmayer, L., Anderer, P. Doseresponse studies with co-dergocrine mesylate under hypoxia utilizing EEG mapping and psychometry. Psychopharmacology 1992, 109: 30-40.
12. Saletu, B., Grunberger, J., Anderer, P., Linzmayer, L., Zyhlarz, G. Effect-kinetics on brain protection of two codergocrine-mesylate preparations (Aramexe retard® and Hydergine®) by EEG mapping and psychometry under hypoxia. Arch Gerontol Geriat 1994, 18 (2): 81-99.
13. Schaffler, K. Pharmakodynamische Bioäquivalenz von Piracetam unter hypoxischer Hypoxie. Arzneim-Forsch/ Drug Res 1986, 26: 845-9.
14. Schaffler, K., Hormann, E., Arnold, H. A pilot study to evaluate the effect of acute and long-term administration of cyclandelate on the vigilance of subjects submitted to hypoxic conditions. Arzneim-Forsch/Drug Res 1981, 31: 1032-5.
15. Maier-Lenz, H., Ringwelski, L., Klein, G., Richter, W. Zur Frage der Wirksamkeitsprüfung von zerebralaktiven Arzneimittein. Vorläufige Mitteilung über ein Modell zur Erprobung zerebralaktiver Arzneimittel an Probanden. ArzneimForsch/Drug Res 1980, 30: 830-2.
16. Saletu, B., Grunberger, J., Anderer, R, Linzmayer, L. Effect of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double-blind, placebo-controlled EEG mapping and psychometric studies under normoxia. Meth Find Exp Clin Pharmacol 1996, 18: 55-56.
17. Anderer, P., Saletu, B., Kinsperger, K., Semlitsch, H. Topographic brain mapping of EEG in neuropsychopharmacology. Part I. Methodological aspects. Meth Find Exp Clin Pharmacol 1987, 9: 371-84.
18. Anderer, P., Semlitsch, H.V., Saletu, B., Barbanoj, M.J. Artifact processing in topographic mapping of electroencephalographic activity in neuropsychopharmacology. Psychiatry Res 1992, 45: 79-93.
19. Saletu, B., Anderer, P., Kinsperger, K., Grünberger, J. Topographic brain mapping of EEG in neuropsychopharmacology, Part II. Clinical applications (Pharmaco-EEG imaging). Meth Find Exp Clin Pharmacol 1987, 9: 385-408.
20. Bartels, P.H., Subach, J.A. Automated interpretation of complex scenes. In: Digital Processing of Biomedical Imagery. Preston, E., Onoe, M. (Eds.). Academic Press: New York 1976, 101-14.
21. Duffy, F.H., Bartels, P.H., Burchfield, J.L. Significance probability mapping: An aid in the topographic analysis of brain electrical activity. Electroencephalogr Clin Neurophysiol 1981, 51: 455-62.
22. Grunberger, J. Psychodiagnostik des Alkoholkranken. Ein methodischer Beitrag zur Bestimmung der Organizitat in der Psychiatrie, Maudrich: Wien 1977.
23. Grünberger, J., Linzmayer, L. Computergesteuerte klinischpsychodiagnostische Methoden in der Psychiatrie. Neuropsychiatrie 1991, 4: 89-98.
24. Von Zerssen, D., Koeller, D.M., Rey, E.R. Die Befindlichkeitsskala (B-S) - ein einfaches Instrument zur Objektivterung von Befindlichkeitsstörungen, insbesondere im Rahmen von Längsschnittuntersuchungen. Arzneim-Forsch/Drug Res 1970, 20: 915-8.
25. Hamer, J., Wiedemann, K., Berlet, H., Weinhardt, F., Hoyer, S. Cerebral glucose and energy metabolism, cerebral oxygen consumption and blood flow in arterial hypoxaemia. Acta Neurochir 1978, 44: 151-60.
26. Hoyer, S. Chronic cerebrovascular disease and brain metabolism at rest: Clinical application to drug studies in middle-aged and elderly patients. In: Drugs and Methods in CVD. SIR (Ed.). Pergamon Press. New York 1981, 131-7.
27. Strughold, H. Hypoxidose. Klin Wochenschr 1944, 23: 221-2.
28. Cahn, J. Influence of aging on the cerebral response to experimental hypoxia and edema. In: Drugs and Methods in CVD. SIR (Ed.). Pergamon Press: New York 1981, 153-62.
29. Takahashi, T. Activation methods. In: Electroencephalography. Niedermayer, E., Lopes da Silva, F. (Eds.). Urban & Schwarzenberg: Baltimore 1982, 179-95.
30. Head, H. The conception of nervous and mental energy. II. Vigilance: A physiological stale of the nervous system. Brit J Psychol 1923, 14: 125-47.
31. Bente, D. Vigilanz: Psychophysiologische Aspekte. Verh Dtsch Ges Inn Med 1977, 83: 945-52.
32. Saletu, B. Application of quantitative EEG in measuring encephalotropic and pharmacodynamic properties of antihypoxidotic/nootropic drugs. In: Drugs and Methods in CVD, SIR (Ed.). Pergamon Press: New York 1981, 79-115.
33. Saletu, B. Neurophysiological aspects of aging and gerontopsychopharmacology. In: Diagnosis and Treatment of Old Age Dementias. Ban, T.A., Lehmann. H.E. (Eds.). Karger: Basel 1989, 43-55.
34. Saletu, B., Grünberger, J. Memory dysfunction and vigilance: Neurophysiological and psychopharmacological aspects. Ann NY Acad Sci 1985, 444: 406-27.
35. Saletu, B. Co-dergocrine type drugs in the pharmacotherapy of mental and cognitive disorders in aging. In: Biological Psychiatry, Vol. 2. Racagni, G., Brunello, N., Fukuda, T. (Eds.). Excerpta Medica: Amsterdam 1991, 163-5.
36. Saletu, B., Anderer, P., Fischhof, P.K., Lorenz, H., Barousch, R., Bohmer, F. EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID. Biol Psychiat 1992, 32: 668-81.
37. Saletu, B., Anderer, P., Paulus, E, et al. EEG brain mapping in diagnostic and therapeutic assessment of dementia. Alzheimer Dis Assoc Disord 1991, 5(1): 57-75.
38. Saletu, B., Paulus, E., Linzmayer, L. et al. Nicergoline in senile dementia of Alzheimer type and multiinfarct dementia: A double-blind, placebo-controlled, clinical and EEG/ ERP mapping study. Psychopharmacology 1995, 117: 385-95.
39. Prawdicz-Neminski, W.W. Zur Kenntnis der elektrischen und der Innervationsvorgänge in den funktionellen Elementen und Geweben des tierischen Organismus. Electrocereprogrogramm der Säugetiere. Pflügers Arch Ges Physiol 1925, 209: 362-82.
40. Berger, H. Über das Elektroencephalogramm des Menschen. Arch Psychiat Nervenkr 1934, 102: 538-57.
41. Gibbs, F.A., Davis, H., Lennox, W.G. The electroencephalogram in epilepsy and in condition of impaired consciousness. Arch Neurol Psychiat 1935, 34: 1133-48.
42. Opitz, E., Schneider, M. Über die Sauerstoffversorgung des Gehirns und den Mechanismus von Mangelwirkungen. Ergeb Physiol 1950, 46: 126-261.
43. Kornmuller, A.E., Palme, F., Strughold, H. Die Ableitung der Gehirnaktionsströme, eine Methode zur Untersuchung der Höhenkrankheit. Klin Wochenschr 1942, 21: 5-8.
44. Opitz, E., Palme, F. Darstellung der Höhenanpassung im Gebirge durch Sauerstoffmangel, II. Mitteilung. Graduierung der Höhenkrankheit durch das Elekiroencephalogramm. Pflugers Arch Ges Physiol 1944, 248: 330-75.
45. Malkin, V.B. Electroencephalogram in acute hypoxic hypoxia. In: Aviation and Space Medicine. Acad Med Sci: Moscow 1963, 348-52.
46. Gurvich, A.M., Ginsburg, D.A. Types of hypoxic and posthypoxic delta activity in animals and man. Electroencephalogr Clin Neurophysiol 1977, 42: 297-308.
47. Saletu, B., Hitzenberger, G., Grünberger, J. et al. Double-blind, placebo-controlled, pharmacokinetic and -dynamic studies with two new formulations of piracetam (infusion and syrup) and hypoxia in man. Int J Clin Pharmacol Ther 1995, 33 (5): 249-62.
48. Saletu, B., Grünberger, J., Anderer, P., Linzmayer, L., König, P. On the cerebro-protective effects of caroverine, a calcium-channel blocker and antiglutamatergic drug: Double-blind, placebo-controlled, EEG mapping and psychometric studies under hypoxia. Brit J Clin Pharmacol 1996, 41.